Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globallyView Video
Firering Strategic Minerals : from explorer to producer
Firering Strategic Minerals: From explorer to producerView Video

Latest Share Chat

UPDATE 1-Britons can be confident in vaccine monitoring, health secretary says

Thu, 08th Apr 2021 09:21

(Adds further quotes on rollout)

LONDON, April 8 (Reuters) - Britons should be confident that
the system to monitor COVID-19 vaccines is working following the
change in advice on giving young people the Oxford-AstraZeneca
jab, Health Secretary Matt Hancock said on Thursday.

"People can be reassured that we have the high class safety
system run by our world class regulator (...) and then we're
totally transparent with all of the side effects, no matter how
extremely rare they are like these ones," he told Sky News.

Britain's vaccine advisory committee said on Wednesday that
an alternative to Oxford-AstraZeneca's vaccine should be given
to under 30s where possible due to a "vanishingly" rare side
effect of blood clots in the brain.

Hancock said new guidance would not delay Britain's
vaccination programme because alternatives from Pfizer
and Moderna would be available for the affected group.

Britain is aiming to give a first dose of COVID-19 vaccine
all over-50s by mid-April and all adults by the end of July.

Hancock said there were 10.16 million people aged between 18
to 29, of whom 1.6 million had already had a first dose of
vaccine.

"We have more than enough Pfizer and Moderna vaccines to
cover all of the remaining eight and a half million people," he
said.

"We are on track to hit the target that we've set that we
will ensure every adult in the UK is offered the jab by the end
of July."
(Reporting by Paul Sandle and Sarah Young; editing by Costas
Pitas and Alistair Smout)

Related Shares

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...

18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.